These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 29477393)

  • 61. The use of exploratory analyses within the National Institute for Health and Care Excellence single technology appraisal process: an evaluation and qualitative analysis.
    Kaltenthaler E; Carroll C; Hill-McManus D; Scope A; Holmes M; Rice S; Rose M; Tappenden P; Woolacott N
    Health Technol Assess; 2016 Apr; 20(26):1-48. PubMed ID: 27049841
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Philosophical concerns regarding cost-effectiveness analyses.
    Weiner BK
    Med Hypotheses; 2010 Feb; 74(2):383-6. PubMed ID: 19651478
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I.
    Berger ML; Mamdani M; Atkins D; Johnson ML
    Value Health; 2009; 12(8):1044-52. PubMed ID: 19793072
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Value of Information Analysis for Research Decisions-An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force.
    Fenwick E; Steuten L; Knies S; Ghabri S; Basu A; Murray JF; Koffijberg HE; Strong M; Sanders Schmidler GD; Rothery C
    Value Health; 2020 Feb; 23(2):139-150. PubMed ID: 32113617
    [TBL] [Abstract][Full Text] [Related]  

  • 65. ACCF/AHA methodology for the development of quality measures for cardiovascular technology: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures.
    Bonow RO; Douglas PS; Buxton AE; Cohen DJ; Curtis JP; Delong E; Drozda JP; Ferguson TB; Heidenreich PA; Hendel RC; Masoudi FA; Peterson ED; Taylor AJ
    J Am Coll Cardiol; 2011 Sep; 58(14):1517-38. PubMed ID: 21880456
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparative effectiveness research as choice architecture: the behavioral law and economics solution to the health care cost crisis.
    Korobkin R
    Mich Law Rev; 2014 Feb; 112(4):523-74. PubMed ID: 24446572
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries.
    Nicod E
    Eur J Health Econ; 2017 Jul; 18(6):715-730. PubMed ID: 27538758
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force.
    Marsh K; IJzerman M; Thokala P; Baltussen R; Boysen M; Kaló Z; Lönngren T; Mussen F; Peacock S; Watkins J; Devlin N;
    Value Health; 2016; 19(2):125-37. PubMed ID: 27021745
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1.
    Jansen JP; Fleurence R; Devine B; Itzler R; Barrett A; Hawkins N; Lee K; Boersma C; Annemans L; Cappelleri JC
    Value Health; 2011 Jun; 14(4):417-28. PubMed ID: 21669366
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Evaluating Frameworks That Provide Value Measures for Health Care Interventions.
    Mandelblatt JS; Ramsey SD; Lieu TA; Phelps CE
    Value Health; 2017 Feb; 20(2):185-192. PubMed ID: 28237193
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Modeling for health care and other policy decisions: uses, roles, and validity.
    Weinstein MC; Toy EL; Sandberg EA; Neumann PJ; Evans JS; Kuntz KM; Graham JD; Hammitt JK
    Value Health; 2001; 4(5):348-61. PubMed ID: 11705125
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making.
    Berger ML; Sox H; Willke RJ; Brixner DL; Eichler HG; Goettsch W; Madigan D; Makady A; Schneeweiss S; Tarricone R; Wang SV; Watkins J; Daniel Mullins C
    Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1033-1039. PubMed ID: 28913966
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Value of Information in Asia: Concepts, Current Use, and Future Directions.
    Dilokthornsakul P; McQueen RB; Chaiyakunapruk N; Spackman E; Watanabe JH; Campbell JD
    Value Health Reg Issues; 2016 May; 9():99-104. PubMed ID: 27881269
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Validity and Reliability of Value Assessment Frameworks for New Cancer Drugs.
    Bentley TGK; Cohen JT; Elkin EB; Huynh J; Mukherjea A; Neville TH; Mei M; Copher R; Knoth R; Popescu I; Lee J; Zambrano JM; Broder MS
    Value Health; 2017 Feb; 20(2):200-205. PubMed ID: 28237195
    [TBL] [Abstract][Full Text] [Related]  

  • 75. What Is Value in Health and Healthcare? A Systematic Literature Review of Value Assessment Frameworks.
    Zhang M; Bao Y; Lang Y; Fu S; Kimber M; Levine M; Xie F
    Value Health; 2022 Feb; 25(2):302-317. PubMed ID: 35094803
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis.
    Garrison LP; Kamal-Bahl S; Towse A
    Value Health; 2017 Feb; 20(2):213-216. PubMed ID: 28237197
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Legislations and policies to expand mental health and substance abuse benefits in health insurance plans: a community guide systematic economic review.
    Jacob V; Qu S; Chattopadhyay S; Sipe TA; Knopf JA; Goetzel RZ; Finnie R; Thota AB;
    J Ment Health Policy Econ; 2015 Mar; 18(1):39-48. PubMed ID: 25862203
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Revolution then evolution: the advance of health economic evaluation in Australia.
    Lopert R; Viney R
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):360-6. PubMed ID: 25444293
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Capturing the value of vaccination within health technology assessment and health economics: Literature review and novel conceptual framework.
    Beck E; Biundo E; Devlin N; Doherty TM; Garcia-Ruiz AJ; Postma M; Sheikh S; Smela B; Toumi M; Wasem J; Nolan T; Salisbury D
    Vaccine; 2022 Jun; 40(30):4008-4016. PubMed ID: 35618559
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Why Value Framework Assessments Arrive at Different Conclusions: A Multiple Myeloma Case Study.
    Westrich K; Buelt L; Dubois RW
    J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S28-S33. PubMed ID: 28535102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.